Objective To investigate the effect of compound isopropyl bromide combined with montelukast sodium on pulmonary function, inflammatory state and symptom improvement in patients with acute exacerbation of bronchial asthma. Methods A total of 111 patients with acute exacerbation of bronchial asthma who were treated in our hospital from February 2021 to February 2022 were selected and divided into two groups according to the random number table method.Among them, 55 patients in the control group received compound ipratropium bromide treatment.In the combined group, 56 patients were treated with montelukast sodium.The pulmonary function indexes, inflammatory factor indexes, related symptom improvement indexes and clinical efficacy were compared between the two groups.Results After treatment, the symptom scores of shortness of breath, wheezing and cough in the combined group were lower than those in the control group; the total effective rate in the combined group was higher than that in the control group; the forced expiratory volume in one second (FEV1), peak expiratory flow in the combined group Peak expiratory flow (PEF) and forced vital capacity (FVC) were higher than those in the control group; factor-α, TNF-α) and interleukin-6 (Interleukin-6, IL-6) were lower than those in the control group (P＜0.05).Conclusion Montelukast sodium combined with compound ipratropium bromide can eliminate related symptoms in patients with bronchial asthma during exacerbation, and improve lung function and inflammatory factor levels.
关键词
支气管哮喘/复方异丙托溴铵/孟鲁司特钠/肺功能
Key words
bronchial asthma/compound ipratropium bromide/montelukast sodium/pulmonary function
万方数据